Upstream Bio will present Phase 2 VALIANT data on verekitug in severe asthma at ERS 2026, putting new efficacy and safety results before investors and clinicians. The Sept. 8 update comes as the company plans pivotal Phase 3 trials; shares traded at $6.62.
published
Upstream Bio will present Phase 2 VALIANT data on verekitug in severe asthma at ERS 2026, putting new efficacy and safety results before investors and clinicians. The Sept. 8 update comes as the company plans pivotal Phase 3 trials; shares traded at $6.62.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.